MX2016011706A - Formulaciones de progesterona. - Google Patents

Formulaciones de progesterona.

Info

Publication number
MX2016011706A
MX2016011706A MX2016011706A MX2016011706A MX2016011706A MX 2016011706 A MX2016011706 A MX 2016011706A MX 2016011706 A MX2016011706 A MX 2016011706A MX 2016011706 A MX2016011706 A MX 2016011706A MX 2016011706 A MX2016011706 A MX 2016011706A
Authority
MX
Mexico
Prior art keywords
formulations
progesterone
progesterone formulations
amount
benefits
Prior art date
Application number
MX2016011706A
Other languages
English (en)
Inventor
Sancilio Frederick
Thorsteinsson Thorsteinn
Cacace Janice
Persicaner Peter
Amadio Julia
Bernick Brian
Original Assignee
Therapeuticsmd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeuticsmd Inc filed Critical Therapeuticsmd Inc
Publication of MX2016011706A publication Critical patent/MX2016011706A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Esta descripción proporciona formulaciones de progesterona, métodos para usar estas formulaciones y sus parámetros farmacocineticos relacionados; relacionados: en modalidades particulares, las formulaciones descritas en la presente descripción permiten una reducción de la cantidad de progesterona administrada a un paciente en necesidad de esta, al mismo tiempo que proporcionan los beneficios de una mayor cantidad de dosificación.
MX2016011706A 2014-03-28 2015-03-27 Formulaciones de progesterona. MX2016011706A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972068P 2014-03-28 2014-03-28
PCT/US2015/023041 WO2015148952A1 (en) 2014-03-28 2015-03-27 Progesterone formulations

Publications (1)

Publication Number Publication Date
MX2016011706A true MX2016011706A (es) 2017-05-01

Family

ID=54196452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011706A MX2016011706A (es) 2014-03-28 2015-03-27 Formulaciones de progesterona.

Country Status (10)

Country Link
EP (1) EP3122364A4 (es)
JP (2) JP2017509630A (es)
KR (1) KR20160137597A (es)
AR (1) AR099872A1 (es)
AU (1) AU2015237243A1 (es)
CA (1) CA2942568A1 (es)
IL (1) IL247828A0 (es)
MX (1) MX2016011706A (es)
RU (1) RU2016136666A (es)
WO (1) WO2015148952A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386757A1 (en) * 2018-10-17 2021-12-16 Sarah S. Stadler Methods of Treating Menopausal Symptoms Using Low Dose Progesterone
CN112336699A (zh) * 2019-08-09 2021-02-09 南京科宁检测科技有限公司 一种黄体酮阴道缓释软胶囊及其制备方法
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AU7709901A (en) * 2000-07-24 2002-02-05 Upjohn Co Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilicdrugs
AU2002242339A1 (en) * 2002-03-14 2003-09-29 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
EA015155B1 (ru) * 2005-05-26 2011-06-30 Тева Вуменс Хелс, Инк. Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US20110312927A1 (en) * 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) * 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies

Also Published As

Publication number Publication date
JP2017509630A (ja) 2017-04-06
AU2015237243A1 (en) 2016-09-29
WO2015148952A1 (en) 2015-10-01
EP3122364A1 (en) 2017-02-01
RU2016136666A3 (es) 2018-11-07
IL247828A0 (en) 2016-11-30
EP3122364A4 (en) 2017-10-25
RU2016136666A (ru) 2018-05-03
JP2019206540A (ja) 2019-12-05
AR099872A1 (es) 2016-08-24
KR20160137597A (ko) 2016-11-30
CA2942568A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
HK1248548A1 (zh) 用於將治療劑和診斷劑遞送到細胞中的方法、組合物和系統
MY187540A (en) Compounds active towards bromodomains
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
PH12017500164A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
EP3234107A4 (en) B cells for in vivo delivery of therapeutic agents
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
EP3229824A4 (en) Oral octreotide administered in combination with other therapeutic agents
MX2017006446A (es) Administracion sublingual de riluzol.
PH12016501841A1 (en) Immunosuppressant formulation
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3337482A4 (en) TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
HK1223630A1 (zh) 抗- 療法的實施與用量
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2016011706A (es) Formulaciones de progesterona.
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
MX2017001512A (es) Compuestos activos hacia bromodominios.
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
MA40553A (fr) Dérivés de pyrimidine substitués par un hétérocyclyle éventuellement condensés utiles pour le traitement des maladies inflammatoires, métaboliques, oncologiques et auto-immunes